“Bevacizumab is associated with a low but meaningful risk for serious gastrointestinal complications, necessitating vigilance, particularly among patients with an intact primary tumour.” from @enenbee @UofTSurgery @CAGS_ACCG in @ColorectalDis https://t.co/
“Bevacizumab is associated with a low but meaningful risk for serious gastrointestinal complications, necessitating vigilance, particularly among patients with an intact primary tumour.” @UofTSurgery @CAGS_ACCG @ColorectalDis https://t.co/Ggi977nwEl
RT @ColorectalDis: Does the Presence of an Intact Primary Increase the Risk of Non‐Elective #colorectalsurgery in Patients Treated with Bev…
RT @ColorectalDis: Does the Presence of an Intact Primary Increase the Risk of Non‐Elective #colorectalsurgery in Patients Treated with Bev…